Peripheral lymphocytosis presenting as EBV/HTLV-1 co-infection adult T-cell leukemia

Kasinathan, Ganesh; Sathar, Jameela

doi:10.1016/j.htct.2020.09.146

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Throughout the clinical course of ATL, EBV coinfection has given rise to features such as lymphadenopathy; hepatosplenomegaly; skin, bone, gastrointestinal, and lung infiltrations; and hypercalcemia. Patients with HTLV-1/EBV coinfections often present aggressive ATLL [40]. Recently, the clinical dermatologic and histopathologic findings associated with cutaneous non-neoplastic and pre-neoplastic disorders with EBV and HTLV-1 coinfection were reviewed and updated to enhance diagnostic and treatment strategies [41].…”

Section: Coinfectionsmentioning

confidence: 99%

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Joseph,

Sandel,

Kulkarni

et al. 2023

Pathogens

View full text Add to dashboard Cite

Infectious agents, notably viruses, can cause or increase the risk of cancer occurrences. These agents often disrupt normal cellular functions, promote uncontrolled proliferation and growth, and trigger chronic inflammation, leading to cancer. Approximately 20% of all cancer cases in humans are associated with an infectious pathogen. The International Agency for Research on Cancer (IARC) recognizes seven viruses as direct oncogenic agents, including Epstein–Barr Virus (EBV), Kaposi’s Sarcoma-associated herpesvirus (KSHV), human T-cell leukemia virus type-1 (HTLV-1), human papilloma virus (HPV), hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus type 1 (HIV-1). Most viruses linked to increased cancer risk are typically transmitted through contact with contaminated body fluids and high-risk behaviors. The risk of infection can be reduced through vaccinations and routine testing, as well as recognizing and addressing risky behaviors and staying informed about public health concerns. Numerous strategies are currently in pre-clinical phases or undergoing clinical trials for targeting cancers driven by viral infections. Herein, we provide an overview of risk factors associated with increased cancer incidence in people living with HIV (PLWH) as well as other chronic viral infections, and contributing factors such as aging, toxicity from ART, coinfections, and comorbidities. Furthermore, we highlight both antibody- and cell-based strategies directed against virus-induced cancers while also emphasizing approaches aimed at discovering cures or achieving complete remission for affected individuals.

show abstract

Section: Coinfectionsmentioning

confidence: 99%

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Joseph,

Sandel,

Kulkarni

et al. 2023

Pathogens

View full text Add to dashboard Cite

show abstract

“…It was the first retrovirus to be associated with development of malignancy [ 97 ]. Approximately 4–7% of HTLV-1-infected individuals develop ATL, which has been correlated with poor prognoses as a result of therapeutic resistance and immunosuppression [ 129 , 130 ].…”

Section: Viruses In Dlbclmentioning

confidence: 99%

“…ATL, resulting from an HTLV-1 infection, is characterized by a long period of latency; the disease appears up to 30 years after primary infection. The highest disease prevalence is observed in Central Africa, Japan and the Caribbean, occurring more commonly in male than female populations with a median age of 40–50 years [ 130 , 132 ].…”

Section: Viruses In Dlbclmentioning

confidence: 99%

Viral Agents as Potential Drivers of Diffuse Large B-Cell Lymphoma Tumorigenesis

Bilajac

Mahmutović

Lundström³

et al. 2022

Viruses

View full text Add to dashboard Cite

Among numerous causative agents recognized as oncogenic drivers, 13% of total cancer cases occur as a result of viral infections. The intricacy and diversity of carcinogenic processes, however, raise significant concerns about the mechanistic function of viruses in cancer. All tumor-associated viruses have been shown to encode viral oncogenes with a potential for cell transformation and the development of malignancies, including diffuse large B-cell lymphoma (DLBCL). Given the difficulties in identifying single mechanistic explanations, it is necessary to combine ideas from systems biology and viral evolution to comprehend the processes driving viral cancer. The potential for more efficient and acceptable therapies lies in targeted medicines that aim at viral proteins or trigger immune responses to either avoid infection or eliminate infected or cancerous cells. In this review, we aim to describe the role of viral infections and their mechanistic approaches in DLBCL tumorigenesis. To the best of our knowledge, this is the first review summarizing the oncogenic potential of numerous viral agents in DLBCL development.

show abstract

Peripheral lymphocytosis presenting as EBV/HTLV-1 co-infection adult T-cell leukemia

Cited by 2 publications

References 18 publications

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Viral Agents as Potential Drivers of Diffuse Large B-Cell Lymphoma Tumorigenesis

Contact Info

Product

Resources

About